CLL

Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.

The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.

In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

In what was once an incurable cancer — chronic lymphocytic leukemia — scientists are seeing remissions that could last for decades.

Here are the top 5 CURE stories for July 2019.

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.

The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.

Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.

 

The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.

Patients with chronic lymphocytic leukemia have newer options that include targeted therapy combinations and CAR-T cell therapy.